Insulin icodec is an ultra-long-acting human insulin analog designed for once-weekly subcutaneous administration. Its prolonged action allows it to provide basal insulin coverage over a longer period than conventional daily basal insulins.
- Once-weekly basal insulin
- Approximately 1-week half-life
- Prolonged insulin action
- Designed to reduce the frequency of basal insulin injections
What is Insulin Icodec?
| Feature | Key information |
|---|---|
| Active ingredient | Insulin icodec-abae |
| Route | Subcutaneous injection |
| Frequency | Once weekly, on the same day each week |
| Strength | 700 units/mL (U-700) |
| Device | Single-patient-use FlexTouch® prefilled pen |
Insulin icodec is a long-acting insulin analog developed to provide basal insulin activity over approximately one week. In the United States, it is marketed as Awiqli® (insulin icodec-abae) and is indicated to improve glycemic control in adults with type 2 diabetes mellitus. Regulatory indications may differ between countries.
The key pharmaceutical feature of insulin icodec is its prolonged duration of action, which allows basal insulin therapy to be administered once weekly rather than once daily.
How Does Insulin Icodec Work?
The prolonged action of insulin icodec is related to changes made to the insulin molecule that influence how it behaves in the body.
- Albumin binding: Insulin icodec reversibly binds to serum albumin, contributing to its prolonged persistence in the circulation.
- Extended half-life: Its elimination half-life is approximately one week, supporting once-weekly dosing.
- Insulin receptor action: It activates the human insulin receptor and produces glucose-lowering effects.
- Sustained exposure: Its prolonged pharmacodynamic profile maintains basal insulin activity across the weekly dosing interval.
Together, these properties allow insulin icodec to remain available in the circulation for an extended period while continuing to provide insulin activity.
What Makes Once-Weekly Insulin Different?
The most noticeable difference between once-weekly insulin icodec and conventional basal insulin therapy is the frequency of administration.
A daily basal insulin regimen may require approximately 365 basal insulin injections in a year, while a once-weekly regimen would require approximately 52. Reducing the number of injections may help lower the treatment burden for appropriately selected patients.
Clinical Evidence: The ONWARDS Program
The ONWARDS clinical development program evaluated once-weekly insulin icodec against once-daily basal insulin comparators.
In the U.S. FDA review of the type 2 diabetes program, five Phase 3 trials, ONWARDS 1–5, randomized 3,765 adults with type 2 diabetes to insulin icodec or daily basal insulin. Icodec demonstrated non-inferiority for HbA1c reduction across all five trials, with statistical superiority in ONWARDS 1–3 and 5.
The clinical studies also examined several aspects of treatment:
- Glycemic control: Pivotal studies showed comparable or better HbA1c reduction versus daily basal insulin.
- Time in range: Studies assessed time in range as an important measure of glycemic control.
- Safety: Hypoglycemia remained an important insulin-related risk requiring appropriate monitoring.
- Indian evidence: A 2025 analysis of 217 Indian participants from ONWARDS 1, 4, and 6 reported comparable efficacy and safety to daily basal insulin comparators.
Why Is This Important for India?
Injection burden can be a practical barrier to insulin initiation and long-term persistence. A once-weekly regimen may simplify basal insulin treatment for appropriately selected adults.
The availability of data from Indian participants also provides useful local clinical context when evaluating this treatment approach.
However, reducing injection frequency alone does not determine the success of insulin therapy. Affordability, access, patient education, correct dosing, glucose monitoring, and clinical follow-up remain important for achieving real-world benefits.
Pharmaceutical Significance
Insulin icodec provides an example of how pharmaceutical science can modify the duration of drug action.
Changes to the insulin molecule influence its protein binding and drug disposition, resulting in a prolonged pharmacokinetic profile. This allows the molecule to remain in circulation for a longer period while maintaining its insulin activity.
The concentrated formulation and dedicated delivery device then translate this pharmacological design into a practical dosage system.
The development of insulin icodec therefore brings together several areas of pharmaceutical science, including molecular modification, biopharmaceutics, pharmacokinetics, formulation science, drug delivery, device technology and clinical pharmacology.
Safety and Important Considerations
Insulin therapy requires appropriate dose selection and monitoring. Because insulin icodec has a prolonged duration of action, switching from another insulin regimen, dose adjustment, and glucose monitoring require particular attention.
Important considerations include:
- Hypoglycemia is an important potential risk with insulin therapy.
- Insulin products and doses should always be verified before administration.
- Changes in insulin regimens should be made under appropriate medical supervision.
- Glucose monitoring is important when changing insulin regimens.
- Patients should follow approved instructions for subcutaneous administration and injection-site rotation.
- The prescribed product should be used according to its approved prescribing information.
Future Perspective
Once-weekly basal insulin represents an important development in patient-centered drug delivery. Further evaluation will help establish its long-term safety, adherence, patient acceptance, affordability, accessibility, and real-world outcomes.
For pharmaceutical scientists, insulin icodec demonstrates how modifying the molecular behavior of a drug can lead to a meaningful change in its dosing frequency.
Conclusion
Insulin icodec represents an important development in basal insulin delivery. Its prolonged pharmacokinetic profile allows basal insulin activity to be maintained over approximately one week, reducing the frequency of injections compared with conventional daily basal insulin therapy.
More importantly, insulin icodec demonstrates how molecular engineering, pharmacokinetics, formulation, and drug-delivery technology can work together to address a practical challenge in insulin therapy.
KEY TAKEAWAY
Insulin icodec demonstrates how molecular modification and pharmaceutical formulation can extend the duration of insulin action, making once-weekly basal insulin therapy possible while maintaining the pharmacological activity required for glucose control.
